H. Riesenberg

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.

C. Bokemeyer, D. Atanackovic, L. Berger, 2013, Lung cancer.

Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report

M. Görner, H. Riesenberg, Frauke Müller, 2012, Journal of Medical Case Reports.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

H. Goldschmidt, E. Nievergall, T. Holderried, 2022, The Lancet. Haematology.

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

H. Goldschmidt, E. Nievergall, T. Holderried, 2021, Blood.

In-patient rehabilitation of lung cancer patients—a prospective study

A. Lübbe, H. Riesenberg, 2010, Supportive Care in Cancer.

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

Michael J. Hoffmann, E. Nievergall, J. Dürig, 2022, HemaSphere.